Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Novo launches Saxenda in US, sees more launches in 2015

(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. The company has said previously it expects sales from the drug to eventually reach $1 billion a year. It said in a statement […]

Read More »

Perrigo Rejects $30B Mylan Bid, Says Deal “Substantially Undervalues” Irish Firm

Pittsburgh, Penn.-based Mylan Inc. (MYL)’s $30 billion unsolicited bid for generic drugmaker Perrigo Company (PRGO) has been rejected by the company, after Perrigo said late Tuesday that the offer “substantially undervalues” Perrigo and “its future growth prospects and “is not in the best interests of Perrigo’s shareholders.” “Perrigo has a long history of driving above […]

Read More »

Biogen (BIIB) Loaded With Talented Women Execs, As CEO Pushes to Diversify Boardroom

Biogen has three women on its 10-member board of directors, an unusual feat in corporate America and the biotech industry. But instead of patting itself on the back with a round of attaboys and attagirls, the Cambridge powerhouse wanted to do more: help other companies put women on their boards. Where to find talented women? […]

Read More »

Amgen Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars

Thousand Oaks, Calif.-based Amgen (AMGN) announced stellar first quarter revenues yesterday, deflecting a failed asthma clinical trial. The company announced a total revenue increase of 11 percent for the first quarter of 2015 compared to the same period last year, rising from $4.521 billion to $5.033 billion. Revenues were driven by sales of Enrel, Prolia, […]

Read More »

Abbott reports first-quarter 2015 results

– FIRST-QUARTER DOUBLE-DIGIT OPERATIONAL SALES GROWTH– FIRST-QUARTER ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.47, ABOVE PREVIOUS GUIDANCE RANGE AND REFLECTING 38 PERCENT GROWTH; GAAP EPS FROM CONTINUING OPERATIONS OF $0.35– FULL-YEAR 2015 EPS GUIDANCE RANGE FOR CONTINUING OPERATIONS REMAINS UNCHANGED– COMPLETES THE SALE OF ITS DEVELOPED MARKETS BRANDED GENERICS PHARMACEUTICALS BUSINESS ABBOTT PARK, Ill., April […]

Read More »

Sangamo BioSciences Reports First Quarter 2015 Financial Results

RICHMOND, Calif., April 22, 2015 /PRNewswire/ — Sangamo BioSciences, Inc. (NASDAQ: SGMO) today reported its first quarter 2015 financial results and accomplishments. For the first quarter ended March 31, 2015, Sangamo reported a consolidated net loss of $5.3 million, or $0.08 per share, compared to a net loss of $7.6 million, or $0.12 per share, for […]

Read More »

Teva Pharmaceuticals Hopes $40 Billion Mylan Deal Will Fuel Stock Rebound

In the red hot market for pharmaceutical deal-making it’s either eat or be eaten. That’s the case with Teva Pharmaceutical’s $82 a share cash and stock bid for generic competitor Mylan, a direct challenge to Mylan’s near $30 billion takeover bid for Perrigo, unveiled on April 8. The question now is whether Mylan’s board of […]

Read More »

XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014

Lenexa, KS (April 21, 2015) – Contract Research Organization XenoTech, LLC, a division of Sekisui, has announced plans to relocate into a new 41,500 ft2 facility.  The planned move will double the size of XenoTech’s global headquarters, currently located at 16825 W. 116th St. in Lenexa, KS.  The new facility, boasting nearly two and a […]

Read More »

EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors

HEMEL HEMPSTEAD, England, April 21, 2015 /PRNewswire/ — EUSA Pharma (EUSA), a recently-established profitable specialty pharmaceutical company with global reach, today announced the appointment of Lee Morley as Chief Executive Officer, and Dr Göran Ando as a Non-Executive Director.  Bryan Morton, who established EUSA Pharma as founder and first CEO, will become Executive Chairman.   […]

Read More »

Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan

DUBLIN, April 21, 2015 /PRNewswire/ — Perrigo Company plc (“Perrigo”) (NYSE: PRGO; TASE) today announced that its Board of Directors has unanimously rejected the unsolicited Proposal (the “Proposal”) from Mylan NV (“Mylan”) (NASDAQ: MYL), disclosed April 8, 2015, to acquire all of the outstanding shares of Perrigo for $205.00 per share. Following a thorough review, advised […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom